Description
Alluvi Retatrutide 20mg – Advanced Triple Agonist Research System
Investigate complex incretin dynamics with Alluvi Retatrutide 20mg. As one of the most significant recent breakthroughs in peptide science, Retatrutide acts as a triple agonist, simultaneously activating GLP-1, GIP, and Glucagon receptors.
This comprehensive, multi-pathway mechanism provides researchers with an exceptional tool to study synergistic metabolic performance, receptor interaction, and cellular energy pathways in controlled in-vitro environments.
This product comes in a premium, user-friendly delivery format featuring a pre-filled dispensing pen engineered for ultimate precision and volumetric consistency during laboratory trials.
Key Features for Researchers
•Next-Generation Triple Agonist: Targets three distinct metabolic pathways (GLP-1, GIP, and Glucagon) for comprehensive synergistic research.
•Pre-Filled Pen System: Ready-to-use solution that completely eliminates the need for manual reconstitution, mixing, or measuring in the lab.
•Optimized 20mg Kit: Perfect for precise dosing control and structured experimental progressions.
•Smooth Delivery: Designed specifically for simple, low-volume dispensing in research models.
Product Specifications
•Total Capacity: 20mg per box
•Dose Configuration: 4 precise volumetric yields of 5mg each
•Format: Solution in a premium pre-filled pen
•Application: For laboratory research and in-vitro use only
Storage & Handling Instructions
•Temperature Control: To ensure maximum peptide stability and long-term effectiveness, this product must be stored in a laboratory refrigerator at 2°C to 8°C. Do not freeze.
•Handling: Always read the included technical leaflet thoroughly before first use to familiarize yourself with the pen dial mechanism and proper dispensing techniques.
⚠️ Research Disclaimer: This product is strictly for research and laboratory purposes only. It is not intended for human consumption, animal use, or medical application. All researchers must handle this compound in accordance with institutional safety protocols.
